

JAN. 16. 2002 12:30PM

TOWNSEND & TOWNSEND

FAX RECEIVED

JAN 17 2001

GROUP 1600

NO. 790

P. 1/14

Atty Docket No. 015389-002616 US

PTO FAX NO.: 1-703-872-9306

ATTENTION: Examiner Not yet assigned  
TELEPHONE NO.:

OFFICIAL

Group Art Unit 1651

**OFFICIAL COMMUNICATION  
FOR THE PERSONAL ATTENTION OF  
EXAMINER Not yet assigned**

**CERTIFICATION OF FACSIMILE TRANSMISSION**


I hereby certify that the following document(s) in re Application of Thomas R. Cech et al., Application No. 09/721,506, filed November 22, 2000 for HUMAN TELOMERASE CATALYTIC SUBUNIT is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Document(s) Attached

1. Transmittal Form (1 page)
2. Information Disclosure Statement (12 pages)

Number of pages being transmitted, including this page: 14

Dated: January 16, 2002

  
Kathy Johnston

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY  
RETURN FACSIMILE AT (650) 326-2422**

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834  
Telephone: 650-326-2400  
Fax: 650-326-2422

PA 3195886 v1

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☒


Approved for use through 10/31/2002, OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/721,506	
	Filing Date	November 22, 2000	
	First Named Inventor	Thomas R. Cech et al.	
	Group Art Unit	1651	
	Examiner Name	Not yet assigned	
Total Number of Pages in This Submission	1	Attorney Docket Number	015389-002616US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm and Individual name	Townsend and Townsend and Crew LLP Hugh Wang Reg. No. 47,163
Signature	
Date	January 16, 2002

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Fax No. (703) 872-9306 on January 16, 2002	
Typed or printed name	Kathy Johnston
Signature	
Date	January 16, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3195882 v1

PATENT

Attorney Docket No.: 015389-002616US  
Client Reference No.: 018/210C

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Thomas R. Cech et al.

Application No.: 09/721,506

Filed: November 22, 2000

For: HUMAN TELOMERASE  
CATALYTIC SUBUNIT: DIAGNOSTIC  
AND THERAPEUTIC METHODS

Examiner: To Be Assigned

Art Unit: 1651

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 08/912,951, filed August 14, 1997 (Attorney Docket No. 015389-002600US). If the examiner would like additional copies of any of these cited references, applicants will happily provide them.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom. As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the

JAN. 16. 2002 12:31PM

TOWNSEND&TOWNSEND

NO. 790


P. 4/14

Thomas R. Cech et al.  
Application No.: 09/721,506  
Page 2

PATENT

Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Hugh Wang  
Reg. No. 47,163

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
HW:adm

PA 3195399 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (8-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 10

**Complete If Known**

Application Number	09/721,506
Filing Date	November 22, 2000
First Named Inventor	Cech, Thomas J.
Group Art Unit	1651
Examiner Name	To Be Assigned
Attorney Docket Number	015389-002616US

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A	08/751,189		Harrington, et al.	11/15/86	
	B	80/039,750		Courter, et al.	02/20/97	
	C	3,817,837		Tanenholtz et al.	08-18-74	
	D	3,850,752		Schuurs et al.	11-26-74	
	E	3,038,350		Kronick et al.	02-17-76	
	F	3,898,345		Ullman et al.	12-01-78	
	G	4,275,149		Litman et al.	06-23-81	
	H	4,277,437		Maggio	07-07-81	
	I	4,386,241		Tom et al.	12-28-82	
	J	4,593,195		Mullis et al.	07-28-87	
	K	4,883,202		Mullis	07-28-87	
	L	4,816,567		Cabilly et al.	03-23-89	
	M	4,865,188		Mullis et al.	10-23-90	
	N	5,489,508		West et al.	02-06-96	
	O	5,583,016		Villeponteau et al.	12-10-98	
	P	5,747,317		Cao	05-05-99	
	Q	5,770,422		Collins	06-23-98	
	R	6,093,809		Cech, et al.	07/25/00	
	S	6,258,535	B1	Villeponteau et al.	07/10/01	
	T	6,261,556	B1	Weinrich et al.	07/17/01	
	U	6,261,838	B1	Cech et al.	07/17/01	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	V	JP	09154578-A			06-17-97	
	W	PCT	WO 84/03584			09-13-84	
	X	PCT	WO 95/13382			05-18-95	
	Y	PCT	WO 96/01835			01-25-96	
	Z	PCT	WO 96/12811			05-02-96	
	AA	PCT	WO 96/19580			08-27-96	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3195399 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (8-00)

Approved for use through 10/31/2002. OMB 0951-0081  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

10

## **Complete if Known**

Application Number	09/721,508
Filing Date	November 22, 2000
First Named Inventor	Cech, Thomas J.
Group Art Unit	1661
Examiner Name	To Be Assigned
Attorney Docket Number	015389-002616US

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Office <sup>2</sup>	Number <sup>2</sup>	Kind Code <sup>5</sup> (if known)				
	AB	PCT	WO 98/40868			12-19-98		
	AC	PCT	WO 98/01542			01-15-98		
	AD	PCT	WO 98/01543			01-15-98		
	AE	PCT	WO 98/07838			03-05-98		
	AF	PCT	WO 98/06938			02-28-98		
	AG	PCT	WO 98/21343			05-22-98		
	AH	PCT	WO 98/37181			03-27-98		
	AI	PCT	WO 98/45450			10-15-98		
	AJ	PCT	WO 98/58040			12/30/98		
	AK	PCT	WO 98/01560			01/14/99		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
 PA 3195399 v1

Please type a plus sign (+) inside this box →



PTO/SB/089 (18-00)

Approved for use through 10/31/2002. OMB 065-00031  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 10

## **Complete if Known**

Application Number	09/721,508
Filing Date	November 22, 2000
First Named Inventor	Cech, Thomas J.
Group Art Unit	1651
Examiner Name	To Be Assigned
Attorney Docket Number	015389-002616US

## **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AL	1994 Genome Issue of <i>Science</i> (265:1981f)	
	AM	Anderson and Young, "Quantitative Filter Hybridization" in <i>Nucleic Acid Hybridization</i> pp73-111 (1985)	
	AN	Ausubel <i>et al.</i> , <i>Current Protocols in Molecular Biology</i> , John Wiley & Sons, New York NY (1989)	
	AO	Autexier <i>et al.</i> , "Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA," (1996) <i>EMBO J.</i> 15:5928	
	AP	Auxier and Greider, "Functional reconstitution of wild-type and mutant <i>Tetrahymena</i> telomerase," (1994) <i>Genes Develop.</i> 8:583	
	AQ	Berger and Kimmel, <i>Guide to Molecular Cloning Techniques</i> , Meth. Enzymol., vol. 152, Academic Press, San Diego CA (1987)	
	AR	Blessman <i>et al.</i> , "Addition of Telomere-Associated HeT DNA Sequences "Heals" Broken Chromosome Ends in <i>Drosophila</i> ," (1990) <i>Cell</i> , 61:883	
	AS	Blitzer <i>et al.</i> , "Expression and secretion vectors for yeast," <i>Meth Enzymol.</i> (1987) 153:516	
	AT	Blackburn and Chlou, "Non-nucleosomal packaging of a tandemly repeated DNA sequence at termini of extrachromosomal DNA coding for rRNA in <i>Tetrahymena</i> ," (1981) <i>Proc. Natl. Acad. Sci.</i> , 78:2263	
	AU	Blackburn and Gell, "A tandemly repeated sequence at the terminus of the extrachromosomal ribosomal RNA genes in <i>Tetrahymena</i> ," (1978) <i>J. Mol. Biol.</i> , 120:33	
	AV	Blackburn, "Telomerases," (1992) <i>Ann. Rev. Biochem.</i> , 61:113	
	AW	Bodnar <i>et al.</i> , "Extension of Life-Span by Introduction of Telomerase Into Normal Human Cells," (1998) <i>Science</i> , 279:349	
	AX	Bradford, "A Rapid and Sensitive method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding," (1976) <i>Anal. Biochem.</i> , 72:248	
	AY	Braunstein <i>et al.</i> , "Transcriptional silencing in yeast is associated with reduced nucleosome acetylation," (1993) <i>Genes Develop.</i> , 7:592	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3195399 v1

Please type a plus sign (+) inside this box →



PTO/SB/088 (3-9-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 10

**Complete if Known**

Application Number	09/721,506
Filing Date	November 22, 2000
First Named Inventor	Cech, Thomas J.
Group Art Unit	1651
Examiner Name	To Be Assigned
Attorney Docket Number	015389-002616US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AZ	Calvio et al., "Identification of hnRNP P2 as TLS/FUS using electrospray mass spectrometry," (1995) <i>RNA</i> , 1:724	
	BA	Caruthers et al., "New chemical methods for synthesizing polynucleotides," (1980) <i>Nucleic Acids Res. Symp. Ser.</i> , 215-223	
	BB	Chan and Tye, "Organization of DNA sequences and replication origins at yeast telomeres," (1989) <i>Cell</i> , 59:583	
	BC	Colbare-Garapin et al., "A new dominant hybrid selective marker for higher eukaryotic cells," (1981) <i>J. Mol. Biol.</i> , 150:1	
	BD	Cole et al., "The EBV-hybridoma technique and its application to human lung cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> , Alan R. Liss Inc., New York NY 77-98 (1985)	
	BE	Collins et al., "Purification of Tetrahymena telomerase and cloning of genes encoding the two protein components of the enzyme," (1995) <i>Cell</i> , 81:677	
	BF	Conrad et al., "RAP1 protein interacts with yeast telomers in vivo: Overproduction alters telomere structure and decreases chromosome stability," (1990) <i>Cell</i> , 63:739	
	BG	Coombs, <i>Dictionary of Biotechnology</i> , Stockton Press, New York NY (1994)	
	BH	Coto et al., "Generation of human monoclonal antibodies reactive with cellular antigens," (1983) <i>Proc. Natl. Acad. Sci.</i> , 80:2026	
	BI	Counter et al., "The catalytic subunit of yeast telomerase," (1997) <i>Proc. Natl. Acad. Sci.</i> , 94:9202	
	BJ	Counter et al., (1994) <i>Proc. Natl. Acad. Sci.</i> , 91:2900	
	BK	Creighton, <i>Proteins, Structures and Molecular Principles</i> , WH Freeman and Co, New York, NY (1983)	
	BL	Dieffenbach and Dveksler, <i>PCR Primer, a Laboratory Manual</i> , Cold Spring Harbor Press, Plainville NY (1995)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burdon Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3195399 v1



Please type a plus sign (+) inside this box →



PTO/SB/08B (8-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 10

**Complete if Known**

Application Number	09/721,506
Filing Date	November 22, 2000
First Named Inventor	Cech, Thomas J.
Group Art Unit	1651
Examiner Name	To Be Assigned
Attorney Docket Number	015389-002616US

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BM	Duplaa <i>et al.</i> , "Quantitative analysis of polymerase chain reaction products using biotinylated dUTP incorporation," (1993) <i>Anal. Biochem.</i> , 212:229	
	BN	Feng <i>et al.</i> , "Oxytricha telomere-binding protein: separable DNA-binding and dimerization domains of the $\alpha$ -subunit," <i>Genes Develop.</i> 7:870 (1993) and Gray <i>et al.</i> , (1991) <i>Cell</i> 67:807	
	BO	Feng <i>et al.</i> , "The RNA Component of Human Telomerase," (1995) <i>Science</i> , 269:1236	
	BP	GenBank Accession No. AA281298	
	BQ	Genbank accession no. AA299678	
	BR	Genbank accession no. AA911750	
	BS	Gilley <i>et al.</i> , "Altering specific telomerase RNA template residues effects active site function," (1995) <i>Genes Develop.</i> , 9:2214	
	BT	Gotteschling and Cech, "Chromatin Structure of the Molecular Ends of Oxytricha Mononuclear DNA: Phased Nucleosomes and a Telomeric Complex," (1994) <i>Cell</i> , 38:501	
	BU	Gotteschling and Zakian, "Telomere proteins: specific recognition and protection of the natural termini of Oxytricha macronuclear DNA," (1986) <i>Cell</i> 47:195	
	BV	Grant <i>et al.</i> , <i>Meth Enzymol.</i> , (1987) 153:516-544	
	BW	Greenwood <i>et al.</i> , "Phylogenetic relationships within the class oligophymetophorea, phylum ciliophora, inferred from the complete small subunit rRNA gene sequences of <i>Colpodium campylum</i> , <i>Glaucoma chattoni</i> , and <i>Opisthanectia henneguyi</i> ," (1991) <i>J. Mol. Evol.</i> , 3:183	
	BX	Greider and Blackburn, "A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis," (1989) <i>Nature</i> , 337:331	
	BY	Greider and Blackburn, "Identification of a specific telomere terminal transferase activity in Tetrahymena extracts," (1985) <i>Cell</i> , 43:405	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3195399 v1

Please type a plus sign (+) inside this box 

PTO/SB/08B (08-00)

Approved for use through 10/31/2002, OMB 0891-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1986, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **6** of **10****Complete If Known**

Application Number	09/721,506
Filing Date	November 22, 2000
First Named Inventor	Cech, Thomas J.
Group Art Unit	1651
Examiner Name	To Be Assigned
Attorney Docket Number	015389-002616US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BZ	Greider, "Telomerase is processive," (1991) <i>Mol. Cell. Biol.</i> , 11:4572	
	CA	Greider, "Telomere Length Regulation," (1996) <i>Ann. Rev. Biochem.</i> , 65:337	
	CB	Hampton <i>et al.</i> , <i>Serological Methods a Laboratory Manual</i> , APS Press, St Paul MN (1980)	
	CC	Harrington <i>et al.</i> , "A Mammalian Telomerase-Associated Protein," (1997) <i>Science</i> , 275:973	
	CD	Harrington <i>et al.</i> , "Human telomerase contains evolutionarily conserved catalytic and structural subunits," (1997) <i>Genes Dev.</i> , 11:3109	
	CE	Hertman and Mulligan, "Two dominant-negative selectable markers for gene transfer studies in mammalian cells," (1986) <i>Proc. Natl. Acad. Sci.</i> , 83:8047	
	CF	Henderson and Blackburn, "An overhanging 3' terminus is a conserved feature of telomeres," (1989) <i>Mol. Cell. Biol.</i> , 9:345	
	CG	Horn <i>et al.</i> , "Synthesis of oligonucleotides on cellulose. Part II: design and synthetic strategy to the synthesis of 22 oligodeoxynucleotides coding for gastric inhibitory polypeptide (GIP)," (1980) <i>Nucleic Acids Res. Symp. Ser.</i> , 225-232	
	CH	Hudson <i>et al.</i> , "An STS-based map of the human genome," (1995) <i>Science</i> , 270:1946	
	CI	Huse <i>et al.</i> , "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda," (1989) <i>Science</i> , 246:1275	
	CJ	Johnson <i>et al.</i> , (1991) <i>Mol. Cell Biol.</i> , 11:1	
	CK	Kilian <i>et al.</i> , "Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types," (1997) <i>Hum. Mol. Genet.</i> , 6:2011	
	CL	Kipling and Cooke, "Hypervariable ultra-long telomeres in mice," (1990) <i>Nature</i> 347:400	
	CM	Klobutcher <i>et al.</i> , "All gene-sized DNA molecules in four species of hypotrichs have the same terminal sequence and an unusual 3' terminus," (1991) <i>Proc. Natl. Acad. Sci.</i> , 78:3015	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3195399 v1

Please type a plus sign (+) inside this box →



PTO/SB/DAB (2-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **7** of **10****Complete if Known**

Application Number	09/721,506
Filing Date	November 22, 2000
First Named Inventor	Cech, Thomas J.
Group Art Unit	1651
Examiner Name	To Be Assigned
Attorney Docket Number	015389-002616US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CN	Koshier and Milestein, "Continuous cultures of fused cells secreting antibody of predefined specificity," (1975) <i>Nature</i> 258:495	
	CO	Kospor <i>et al.</i> , "The production of monoclonal antibodies from human lymphocytes," (1983) <i>Immunol. Today</i> 4:72	
	CP	Lamond and Sproat, (1994) "Isolation and Characterization of Ribonucleoprotein Complexes," pp 103-140	
	CQ	Lamond <i>et al.</i> , "Probing the structure and function of U2 snRNP with antisense oligonucleotides made of 2'-OMe RNA," (1989) <i>Cell</i> , 59:393	
	CR	Londvay <i>et al.</i> , "Senescence mutants of <i>Saccharomyces cerevisiae</i> with a defect in telomere replication identify three additional EST genes," (1996) <i>Genetics</i> , 144	
	CS	Lingner <i>et al.</i> , "Purification of telomerase from <i>Euplotes adiculatus</i> : requirement of a primer 3' overhang," (1996) <i>Proc. Natl. Acad. Sci.</i> , 93:10712	
	CT	Lingner <i>et al.</i> , "Reverse transcriptase motifs in the catalytic subunit of telomerase," (1997) <i>Science</i> , 278:581	
	CU	Lingner <i>et al.</i> , "Telomerase RNAs of different ciliates have a common secondary structure and a permuted template," (1994) <i>Genes Develop.</i> , 8:1984	
	CV	Lingner <i>et al.</i> , "Telomerase and DNA End Replication: No Longer a Lagging Strand Problem?," (1995) <i>Science</i> 269:1533	
	CW	Lowy <i>et al.</i> , "Isolation of transforming DNA: Cloning the hamster apt gene," (1980) <i>Cell</i> , 22:817	
	CX	Lusig and Peles, Identification of yeast mutants with altered telomere structure," (1986) <i>Proc. Natl. Acad. Sci.</i> , 83:1398	
	CY	Maddox <i>et al.</i> , "Elevated serum levels in human pregnancy of a molecule immunohistochemically similar to eosinophil granule major basic protein," (1983) <i>J. Exp. Med.</i> , 158:1211	
	CZ	Makarova <i>et al.</i> , "Nucleosomal Organization of Telomere-Specific Chromatin in Rat," (1993) <i>Cell</i> , 73:775	
	DA	McEachern and Blackburn, "runaway telomere elongation caused by telomerase RNA gene mutation," (1995) <i>Nature</i> , 376:403	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burdan Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3195399 v1

Please type a plus sign (+) inside this box →



PTO/SB/09B (C-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **8** of **10****Complete if Known**

Application Number	09/721,506
Filing Date	November 22, 2000
First Named Inventor	Cech, Thomas J.
Group Art Unit	1651
Examiner Name	To Be Assigned
Attorney Docket Number	015389-002616US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	2
	DB	Melby <i>et al.</i> , "Quantitative measurement of human cytokine gene expression by polymerase chain reaction," (1993) <i>J. Immunol. Meth.</i> , 159:235	
	DC	Merrifield, "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide," (1965) <i>J. Am. Chem. Soc.</i> , 85:2140	
	DD	Meyerson <i>et al.</i> , "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization," (1997) <i>Cell</i> , 90:785	
	DE	Murray, <i>In McGraw Hill Yearbook of Science and Technology</i> , (1992) McGraw Hill, New York NY, pp 191-196	
	DF	Nakamura <i>et al.</i> , "Telomerase Catalytic Subunit Homologs from Fission Yeast and Human," (1997) <i>Science</i> , 277:956	
	DG	Nakayama <i>et al.</i> , "TLP1: A Gene Encoding a Protein Component of Mammalian Telomerase Is a Novel Member of WD Repeats Family," (1997) <i>Cell</i> , 88:375	
	DH	Nielsen <i>et al.</i> , (1993) "Peptide nucleic acids (PNAs): Potential antisense and anti-gene agents," <i>Anticancer Drug Des.</i> , 8:53	
	DI	Oka <i>et al.</i> , "Inverted terminal repeat sequence in the macronuclear DNA of <i>Stylenychia pustulata</i> ," (1980) <i>Gene</i> , 10:301	
	DJ	Olovnikov, "A theory of marginotomy: The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon," (1973) <i>J. Theor. Biol.</i> , 41:181	
	DK	Orlandi <i>et al.</i> , "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," (1989) <i>Proc. Natl. Acad. Sci.</i> , 86:3833	
	DL	Prescott, "The DNA of ciliated protozoa," (1994) <i>Microbiol. Rev.</i> , 58:233	
	DM	Price, (1993) <i>Blood Rev.</i> , 7:127	
	DN	Rhodes <i>et al.</i> , "Transformation of maize by electroporation of embryos," (1995) <i>Meth. Mol. Biol.</i> , 55:121	
	DO	Roberge <i>et al.</i> , "A strategy for a convergent synthesis of N-linked glycopeptides on a solid support," (1995) <i>Science</i> , 269:202	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 9195399 v1

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (01-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1440B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 10

**Complete if Known**

Application Number	09/721,506
Filing Date	November 22, 2000
First Named Inventor	Cech, Thomas J.
Group Art Unit	1651
Examiner Name	To Be Assigned
Attorney Docket Number	015389-002616US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	2
	DP	Romero and Blackburn, "A conserved secondary structure for telomerase RNA, " (1991) <i>Cell</i> , 67:343	
	DQ	Sambrook <i>et al.</i> , <i>Molecular Cloning, A Laboratory Manual</i> , Cold Spring Harbor Press, Plainview NY (1989)	
	DR	Sandell <i>et al.</i> , "Transcription of yeast telomere alleviates telomere position effect without affecting chromosome stability," (1994) <i>Proc. Natl. Acad. Sci.</i> , 91:12081	
	DS	Sanger <i>et al.</i> , "DNA sequencing with chain-terminating inhibitors," (1977) <i>Proc. Natl. Acad. Sci.</i> , 74:5463	
	DT	Scharf <i>et al.</i> , "Heat stress promoters and transcription factors," (1994) <i>Resault Probl. Cell Differ.</i> 20:125	
	DU	Shampay and Blackburn, "Generation of telomere-length heterogeneity in <i>Saccharomyces cerevisiae</i> ," (1988) <i>Proc. Natl. Acad. Sci.</i> , 85:534	
	DV	Sheen and Lovis, "Transposition of the LINE-like retrotransposon TART to <i>Drosophila</i> chromosome termini," (1994) <i>Proc. Natl. Acad. Sci.</i> , 91:12510	
	DW	Singer and Gottschling, "TLC1: Template RNA Component of <i>Saccharomyces cerevisiae</i> Telomerase," (1994) <i>Science</i> 266:404	
	DX	Starling <i>et al.</i> , "Extensive telomere repeat arrays in mouse are hypervariable," (1990) <i>Nucleic Acids Res.</i> , 18:6881	
	DY	Swanton <i>et al.</i> , "Arrangement of Coding and Non-coding Sequences in the DNA Molecules Coding for rRNAs in <i>Oxytricha</i> sp.," (1980) <i>Chromosoma</i> 77:203	
	DZ	Tommerup <i>et al.</i> , "Unusual chromatin in human telomeres," (1994) <i>Mol. Cell. Biol.</i> , 14:5777	
	EA	Trask, "Fluorescence in situ hybridization: application in cytogenetics and gene mapping," (1991) <i>Trends Genet.</i> , 7:149	
	EB	Verma <i>et al.</i> , "Human Chromosomes: A Manual of Basic Techniques," Pergamon Press, New York NY (1988)	
	EC	Watson, "Origin of concatemeric TT DNA, " (1972) <i>Nature New Biol.</i> , 239:197	

Examiner  
SignatureDate  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3195399 v1

Please type a plus sign (+) inside this box ☐

PTO/SB/08B (0-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **10** of **10****Complete if Known**

Application Number	09/721,506
Filing Date	November 22, 2000
First Named Inventor	Cech, Thomas J.
Group Art Unit	1651
Examiner Name	To Be Assigned
Attorney Docket Number	015389-002616US

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	2
	ED	Weinrich <i>et al.</i> , "Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT," (1997) <i>Nat. Genet.</i> , 17(4):498	
	EE	Wellinger <i>et al.</i> , "Origin activation and formation of single-strand TG <sub>1-3</sub> tails occur sequentially in late S phase on a Yeast linear plasmid," (1993) <i>Mol. Cell. Biol.</i> , 13:4057	
	EF	Wellinger <i>et al.</i> , "Saccharomyces Telomeres Acquire Single-Strand TG <sub>1-3</sub> Tails Late in S Phase," (1993) <i>Cell</i> 72:61	
	EG	Whitehead Institute/MIT Center for Genome Research, Genetic Map of the Mouse, Database Release 10, April 26, 1995	
	EH	Wigler <i>et al.</i> , "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells," (1977) <i>Cell</i> , 11:223	
	EI	Wigler <i>et al.</i> , "Transformation of mammalian cells with an amplifiable dominant-acting gene," (1980) <i>Proc. Natl. Acad. Sci.</i> , 77:3667	
	EJ	Winter and Milstein, "Man-made antibodies," (1991) <i>Nature</i> , 348:293	
	EK	Wright <i>et al.</i> , "Saccharomyces telomeres assume a non-nucleosomal chromatin structure," (1992) <i>Genes Develop.</i> , 6:197	
	EL	Yu <i>et al.</i> , "In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs," (1990) <i>Nature</i> , 344:126	
	EM	Zahler and Prescott, "Telomere terminal transferase activity in the hypotrichous ciliate <i>Oxytricha nova</i> and a model for replication of the ends of linear DNA molecules," (1988) <i>Nucleic Acids Res.</i> , 16:6953	
	EN	Zaklan, "Telomeres: Beginning to Understand the End," (1995) <i>Science</i> 270:1601	
	EO	Zaug <i>et al.</i> , "Catalysis of RNA Cleavage by a Ribozyme Derived from the Group I Intron of <i>Anabaena</i> Pre-tRNA <sup>Leu</sup> ,"	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3195399 v1